Canada markets open in 4 hours 23 minutes

Onconova Therapeutics, Inc. (ONTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0500-0.1200 (-3.79%)
At close: 04:00PM EST
3.0500 0.00 (0.00%)
Pre-Market: 04:14AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.1700
Open3.2000
Bid0.0000 x 3200
Ask0.0000 x 1300
Day's Range3.0500 - 3.2300
52 Week Range2.8900 - 28.9500
Volume225,497
Avg. Volume2,040,317
Market Cap63.716M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-1.2820
Earnings DateNov. 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • GlobeNewswire

    Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

    NEWTOWN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 29, 2021 through December 2, 2021. A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-dem

  • GlobeNewswire

    Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

    Conference call and live webcast at 4:30 p.m. ET todayNEWTOWN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended September 30, 2021, and provided a business update. Highlights for the third quarter of 2021 and subsequent weeks include: The Phase 1 solid tumor studies of

  • Zacks

    Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.